Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT path...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Elizabeth K., Tan-Wasielewski, Zhenying, Aghajanian, Carol, Coleman, Robert L., Curtis, Jennifer, Hirsch, Michelle S., Matulonis, Ursula A., Cantley, Lewis C., Mills, Gordon B., Doyle, L. Austin, Liu, Joyce F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021536/
https://www.ncbi.nlm.nih.gov/pubmed/32083163
http://dx.doi.org/10.1016/j.gore.2020.100546
_version_ 1783497896528707584
author Lee, Elizabeth K.
Tan-Wasielewski, Zhenying
Aghajanian, Carol
Coleman, Robert L.
Curtis, Jennifer
Hirsch, Michelle S.
Matulonis, Ursula A.
Cantley, Lewis C.
Mills, Gordon B.
Doyle, L. Austin
Liu, Joyce F.
author_facet Lee, Elizabeth K.
Tan-Wasielewski, Zhenying
Aghajanian, Carol
Coleman, Robert L.
Curtis, Jennifer
Hirsch, Michelle S.
Matulonis, Ursula A.
Cantley, Lewis C.
Mills, Gordon B.
Doyle, L. Austin
Liu, Joyce F.
author_sort Lee, Elizabeth K.
collection PubMed
description Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss.
format Online
Article
Text
id pubmed-7021536
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-70215362020-02-20 Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035) Lee, Elizabeth K. Tan-Wasielewski, Zhenying Aghajanian, Carol Coleman, Robert L. Curtis, Jennifer Hirsch, Michelle S. Matulonis, Ursula A. Cantley, Lewis C. Mills, Gordon B. Doyle, L. Austin Liu, Joyce F. Gynecol Oncol Rep Case Series Platinum-resistant, recurrent, high grade epithelial ovarian carcinoma remains challenging to treat. Chemotherapy produces limited responses with modest survival benefits in the treatment of recurrent disease. In this context, targeted therapies may improve upon conventional therapies. PI3K/AKT pathway alterations are frequently found in several cancer types, including ovarian cancer, and thus AKT inhibition is a rational targeted therapy. Here we report the results of an abbreviated trial of AKT inhibitor MK-2206 in platinum resistant high grade serous ovarian, fallopian tube, and primary peritoneal cancer with PTEN loss. Elsevier 2020-02-03 /pmc/articles/PMC7021536/ /pubmed/32083163 http://dx.doi.org/10.1016/j.gore.2020.100546 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Series
Lee, Elizabeth K.
Tan-Wasielewski, Zhenying
Aghajanian, Carol
Coleman, Robert L.
Curtis, Jennifer
Hirsch, Michelle S.
Matulonis, Ursula A.
Cantley, Lewis C.
Mills, Gordon B.
Doyle, L. Austin
Liu, Joyce F.
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
title Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
title_full Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
title_fullStr Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
title_full_unstemmed Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
title_short Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
title_sort results of an abbreviated phase ii study of akt inhibitor mk-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (nct 01283035)
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021536/
https://www.ncbi.nlm.nih.gov/pubmed/32083163
http://dx.doi.org/10.1016/j.gore.2020.100546
work_keys_str_mv AT leeelizabethk resultsofanabbreviatedphaseiistudyofaktinhibitormk2206inthetreatmentofrecurrentplatinumresistanthighgradeserousovarianfallopiantubeorprimaryperitonealcarcinomanct01283035
AT tanwasielewskizhenying resultsofanabbreviatedphaseiistudyofaktinhibitormk2206inthetreatmentofrecurrentplatinumresistanthighgradeserousovarianfallopiantubeorprimaryperitonealcarcinomanct01283035
AT aghajaniancarol resultsofanabbreviatedphaseiistudyofaktinhibitormk2206inthetreatmentofrecurrentplatinumresistanthighgradeserousovarianfallopiantubeorprimaryperitonealcarcinomanct01283035
AT colemanrobertl resultsofanabbreviatedphaseiistudyofaktinhibitormk2206inthetreatmentofrecurrentplatinumresistanthighgradeserousovarianfallopiantubeorprimaryperitonealcarcinomanct01283035
AT curtisjennifer resultsofanabbreviatedphaseiistudyofaktinhibitormk2206inthetreatmentofrecurrentplatinumresistanthighgradeserousovarianfallopiantubeorprimaryperitonealcarcinomanct01283035
AT hirschmichelles resultsofanabbreviatedphaseiistudyofaktinhibitormk2206inthetreatmentofrecurrentplatinumresistanthighgradeserousovarianfallopiantubeorprimaryperitonealcarcinomanct01283035
AT matulonisursulaa resultsofanabbreviatedphaseiistudyofaktinhibitormk2206inthetreatmentofrecurrentplatinumresistanthighgradeserousovarianfallopiantubeorprimaryperitonealcarcinomanct01283035
AT cantleylewisc resultsofanabbreviatedphaseiistudyofaktinhibitormk2206inthetreatmentofrecurrentplatinumresistanthighgradeserousovarianfallopiantubeorprimaryperitonealcarcinomanct01283035
AT millsgordonb resultsofanabbreviatedphaseiistudyofaktinhibitormk2206inthetreatmentofrecurrentplatinumresistanthighgradeserousovarianfallopiantubeorprimaryperitonealcarcinomanct01283035
AT doylelaustin resultsofanabbreviatedphaseiistudyofaktinhibitormk2206inthetreatmentofrecurrentplatinumresistanthighgradeserousovarianfallopiantubeorprimaryperitonealcarcinomanct01283035
AT liujoycef resultsofanabbreviatedphaseiistudyofaktinhibitormk2206inthetreatmentofrecurrentplatinumresistanthighgradeserousovarianfallopiantubeorprimaryperitonealcarcinomanct01283035

Ejemplares similares